PMID- 11106926
OWN - NLM
STAT- MEDLINE
DCOM- 20001222
LR  - 20190813
IS  - 0300-0664 (Print)
IS  - 0300-0664 (Linking)
VI  - 53
IP  - 5
DP  - 2000 Nov
TI  - Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the 
      HGF/SF receptor (cMET) are associated with a high risk of metastasis and 
      recurrence for children and young adults with papillary thyroid carcinoma.
PG  - 635-44
AB  - OBJECTIVE: The study determined if hepatocyte growth factor/scatter factor 
      (HGF/SF) or the HGF/SF receptor (cMET) might be important for metastasis in 
      thyroid cancer. DESIGN: We examined HGF/SF and cMET expression by 
      immunohistochemistry in a retrospective group of benign and malignant thyroid 
      lesions from children and young adults, and correlated the intensity of 
      expression with clinical outcome. PATIENTS: Patients included 42 children and 
      young adults with papillary thyroid carcinomas (PTC), seven with follicular 
      thyroid carcinomas (FTC), two with medullary thyroid carcinomas (MTC), 14 with 
      benign thyroid disorders, and two with normal thyroids. MEASUREMENTS: Expression 
      of cMET was graded from 0 (absent) to 4 (intense); and HGF/SF expression was 
      graded from 0 (absent-minimal) to 3 (diffuse and intense). RESULTS: cMET staining 
      was greater in PTC (mean intensity 2.3 +/- 0.4 vs. 0.8 +/- 0.2, P < 0.005) and 
      FTC (2.4 +/- 0.6 vs. 0.8 +/- 0.2, P = 0.04) than benign lesions (0.8 +/- 0.2) or 
      normal thyroids (0.4 +/- 0.5). PTC with intense cMET staining had shorter disease 
      free survival (P = 0.05) and increased HGF/SF staining (r = 0.39, P = 0.017). 
      HGF/SF correlated with the extent of disease at diagnosis (r = 0.33, P = 0.049). 
      Patients with PTC were stratified into quartiles based on combined cMET and 
      HGF/SF staining. Those with intense cMET and HGF/SF staining were younger (P = 
      0.05), and had reduced disease free survival (P = 0.03). CONCLUSIONS: We conclude 
      that increased cMET and HGF/SF expression is associated with a high risk for 
      metastasis and recurrence in children and young adults with papillary thyroid 
      carcinoma.
FAU - Ramirez, R
AU  - Ramirez R
AD  - Department of Paediatrics, Walter Reed Army Medical Center, Washington, DC, USA.
FAU - Hsu, D
AU  - Hsu D
FAU - Patel, A
AU  - Patel A
FAU - Fenton, C
AU  - Fenton C
FAU - Dinauer, C
AU  - Dinauer C
FAU - Tuttle, R M
AU  - Tuttle RM
FAU - Francis, G L
AU  - Francis GL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Carcinoma, Papillary/*metabolism/secondary
MH  - Child
MH  - Disease-Free Survival
MH  - Female
MH  - Hepatocyte Growth Factor/*metabolism
MH  - Humans
MH  - Male
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local/*metabolism
MH  - Neoplasm Staging
MH  - Proto-Oncogene Proteins c-met/*metabolism
MH  - Retrospective Studies
MH  - Thyroid Neoplasms/*metabolism/pathology
EDAT- 2000/12/07 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/12/07 11:00
PHST- 2000/12/07 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/12/07 11:00 [entrez]
AID - cen1124 [pii]
AID - 10.1046/j.1365-2265.2000.01124.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2000 Nov;53(5):635-44. doi: 
      10.1046/j.1365-2265.2000.01124.x.